Literature DB >> 15986360

Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia.

Silvia S Pierangeli1, Guillermina Girardi, Mariano Vega-Ostertag, Xiaowei Liu, Ricardo G Espinola, Jane Salmon.   

Abstract

OBJECTIVE: Antiphospholipid antibodies (aPL) have been shown to induce thrombosis, activate endothelial cells, and induce fetal loss. The pathogenesis of aPL-induced thrombosis, although not completely understood, may involve platelet and endothelial cell activation as well as procoagulant effects of aPL directly on clotting pathway components. Recent studies have shown that uncontrolled complement activation leads to fetal death in aPL-treated mice. In this study, we tested the hypothesis that aPL are responsible for activation of complement, thus generating split products that induce thrombosis.
METHODS: To study thrombus dynamics and adhesion of leukocytes we used in vivo murine models of thrombosis and microcirculation, in which injections of aPL were used.
RESULTS: Mice deficient in complement components C3 and C5 were resistant to the enhanced thrombosis and endothelial cell activation that was induced by aPL. Furthermore, inhibition of C5 activation using anti-C5 monoclonal antibodies prevented thrombophilia induced by aPL.
CONCLUSION: These data show that complement activation mediates 2 important effectors of aPL, induction of thrombosis and activation of endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15986360     DOI: 10.1002/art.21157

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  89 in total

Review 1.  Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers.

Authors:  Shruti Chaturvedi; Keith R McCrae
Journal:  Curr Rheumatol Rep       Date:  2017-07       Impact factor: 4.592

Review 2.  Is there a microangiopathic antiphospholipid syndrome?

Authors:  Ronald A Asherson; Sylvia S Pierangeli; Ricard Cervera
Journal:  Ann Rheum Dis       Date:  2007-04       Impact factor: 19.103

Review 3.  The role of complement in the antiphospholipid syndrome-associated pathology.

Authors:  Ingrid Avalos; George C Tsokos
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

4.  Primary antiphospholipid syndrome presenting as HELLP syndrome: a clinical pathology conference held by the Division of Rheumatology at Hospital for Special Surgery.

Authors:  Diane George; Lisa Vasanth; Doruk Erkan; Anne Bass; Jane Salmon; Michael D Lockshin
Journal:  HSS J       Date:  2007-04-26

Review 5.  Pathogenic role of antiphospholipid antibodies.

Authors:  J E Salmon; P G de Groot
Journal:  Lupus       Date:  2008-05       Impact factor: 2.911

Review 6.  The journey of antiphospholipid antibodies from cellular activation to antiphospholipid syndrome.

Authors:  Rohan Willis; E B Gonzalez; A R Brasier
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

7.  In Vivo Role of Neutrophil Extracellular Traps in Antiphospholipid Antibody-Mediated Venous Thrombosis.

Authors:  He Meng; Srilakshmi Yalavarthi; Yogendra Kanthi; Levi F Mazza; Megan A Elfline; Catherine E Luke; David J Pinsky; Peter K Henke; Jason S Knight
Journal:  Arthritis Rheumatol       Date:  2017-03       Impact factor: 10.995

Review 8.  Renal involvement in primary antiphospholipid syndrome.

Authors:  Carmelita Marcantoni; Carmela Emmanuele; Francesco Scolari
Journal:  J Nephrol       Date:  2016-05-19       Impact factor: 3.902

Review 9.  Complement and autoimmunity.

Authors:  Eleonora Ballanti; Carlo Perricone; Elisabetta Greco; Marta Ballanti; Gioia Di Muzio; Maria Sole Chimenti; Roberto Perricone
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

Review 10.  Tissue factor in antiphospholipid antibody-induced pregnancy loss: a pro-inflammatory molecule.

Authors:  G Girardi; N Mackman
Journal:  Lupus       Date:  2008-10       Impact factor: 2.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.